SUMMARY Seven women with primary pulmonary hypertension underwent hemodynamic evaluation, at rest and during exercise, before and after the oral administration of captopril. Dose-response curves were generated for the 25-, 50-and 100-mg doses. Captopril significantly reduced systemic blood pressure and systemic vascular resistance; these effects persisted at submaximal levels of exercise. Captopril did not alter pulmonary artery pressure or resistance, cardiac output or stroke volume at rest or during exercise.
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Exercise tolerance did not improve. Four of the patients also received captopril chronically for 12 weeks at doses of 75 and 100 mg every 8 hours. Resting and exercise hemodynamic evaluation was repeated at the end of the 12-week period. Except for a persistent reduction in mean systemic blood pressure at rest, chronic captopril administration did not elicit hemodynamic changes. Measured exercise duration did not change during continuous captopril treatment, although one patient reported mild subjective improvement in activity tolerance.
In primary pulmonary hypertension, captopril exerts its major effect on systemic vasculature, with little or no effect on the pulmonary circuit. While an occasional patient may experience some clinical improvement with captopril therapy, the majority of adult patients with severe primary pulmonary hypertension will not benefit from its chronic administration.
THE CURRENT treatment regimens of primary pulmonary hypertension are generally inadequate. Numerous reports have shown favorable clinical and hemodynamic responses in an individual or a small group of patients to phentolamine,l isoproterenol,2' diazoxide5 6 or hydralazine.7 However, no one vasodilator is of major benefit in the majority of patients.
Captopril is a relatively new drug whose effects are mediated primarily through the inhibition of angiotensin I-*angiotensin II-converting enzyme. This drug decreases systemic blood pressure in patients with systemic hypertension'-" and reduces systemic and pulmonary vascular resistances in patients with congestive heart failure.'2 ''4 Although the mechanisms of primary pulmonary hypertension are not known, most of the body's converting enzyme is in the lungs."
This study was performed to determine if captopril can elicit favorable hemodynamic effects, particularly in the pulmonary vasculature, in patients with primary pulmonary hypertension and to investigate (albeit indirectly) the role of angiotensin and converting enzyme in this disease.
Methods

Patients
Seven adult female patients, mean age 40 years (range 24-54 years), with primary pulmonary hypertension were studied. The mean duration of symptoms was 37 months. At the time of entry into the study, patients 1, 4, 5, 6 and 7 were limited by dyspnea or fatigue with mild exertion, patient 3 by dyspnea on mild exertion and moderate peripheral edema, and patient 2 by fatigue and angina with mild exertion. Patients 1, 2 and 4 had one or more syncopal or nearsyncopal episodes in the year before the study. None of the patients had a history of taking birth control pills or any other hormonal preparation. All patients had evidence of elevated pulmonary artery and right heart pressures and right ventricular hypertrophy on physical examination. Features of right atrial and ventricular enlargement were present on the ECG and the chest roentgenograms of each patient. Cardiac catheterization, selective pulmonary angiography and left ventricular and coronary cineangiography were performed within 2 months of this study. Patients with secondary forms of pulmonary hypertension or an additional cardiac abnormality were excluded from study. The hemodynamic data obtained during diagnostic catheterization were comparable to those presented in this report. Patients 1, 4, 6 and 7 were receiving oral digoxin (0.125-0.25 mg/day) and patients 3, 6 and 7 were taking furosemide (20-40 mg/day). These drugs and doses were continued throughout the study period, with p.m. dosing to avoid the potential hemodynamic effects of peak absorption. Cardiac index, stroke volume index, pulmonary vascular resistance, systemic vascular resistance, and mean systemic blood pressure were calculated by standard formulas.
Protocol
The hemodynamic response to oxygen and isoproterenol was assessed on day 1. After a 2-hour equilibration period, after the pulmonary artery catheter insertion, baseline hemodynamic measurements were made in duplicate (20-minute interval) and averaged. Oxygen was then administered by mask at ¢ 90% inhalation concentration. Hemodynamic measurements were made after 30 minutes of oxygen. After these measurements, oxygen was discontinued and the patient was allowed to re-equilibrate over the next 2 hours. Baseline hemodynamic studies were repeated. Isoproterenol, 0.25 mg/kg, was administered sublingually, followed by hemodynamic measurements at 15, 30 and 60 minutes. Peak effects occurred at 30 minutes; the 30-minute values are presented in figure 1 to show the hemodynamic responsiveness to isoproterenol.
All studies involving captopril were performed in the postabsorptive state between 0700 and 1400 hours. Baseline resting hemodynamic measurements were made in duplicate (20-30-minute interval) and averaged. After baseline measurements, captopril was administered: 25 mg orally on day 2, 50 mg on day 3 and 100 mg on day 4. Resting hemodynamic measurements were made 30, 60, 90, 120, 180, 240, 300 and 360 minutes after each dose.
Exercise studies were performed on day 5. Upright (sitting) hemodynamic measurements were made at rest, at 180-second intervals during exercise and at maximal exercise. Exercise was started at a work load of 50 kg-m/min advanced to 100 kg-m/min at 180 seconds, and subsequently increased by 100-kg-m/min increments at 180-second intervals. Maximal exercise duration was taken as the time the exercise was discontinued because of severe dyspnea or fatigue. The ergometry study was performed before captopril and 1 /2-2 hours afterwards. The captopril dose selected for evaluation during exercise was the dose that elicited the maximal responses in hemodynamic measurements made at rest (days 2, 3, and 4) with the fewest undesirable effects (hypotension, near-syncope, chest pain, nausea and vomiting). This dose was 100 mg in four patients, 75 mg in one patient and 25 mg in one. One patient performed less than 60 seconds of exercise and was excluded from the exercise phase of study.
Patients 1, 3, 5 and 6 agreed to participate in the chronic administration phase of study. They continued taking captopril for 3 months: three patients took 100 mg and one patient 75 mg every 8 hours. The patients were rehospitalized at the end of the 3-month period. Dosing was not interrupted. Resting and exercise hemodynamic measurements were made before and 1 1/2-2 hours after the 0800 dose of captopril. nary vascular resistance over 6 hours after administration (table 1) . Individual pulmonary hemodynamic responses to captopril varied, but the responses were not particularly striking for any patient (table 1) . At these doses, captopril decreased systemic blood pressure and systemic vascular resistance significantly. The responses of systemic blood pressure and systemic vascular resistance to the three doses did not differ significantly from each other. The pulmonary vascular resistance/systemic vascular resistance and the pulmonary arterial pressure/systemic blood pressure ratios increased significantly after captopril (table 1) FIGURE 3. Individual and group-mean responses in pulmonary arterial pressure, pulmonary vascular resistance, systemic blood pressure and systemic vascular resistance of the four patients who underwent the chronic captopril phase of study. Measurements were made at baseline control (Cont), 1J/2-2 hours after acute dosing (A Cap) and 1J/2-2 hours after a dose after 12 weeks ofchronic administration (C Cap). The hemodynamic measurements were made at rest, after 3 minutes of exercise and at maximal exercise (Max). that chronic dosing with captopril increases lung and serum converting-enzyme activity in rats. Therefore, the potential beneficial effects of captopril may have been mitigated by the induction of converting enzyme. The role of angiotensin II itself in the regulation of pulmonary vascular tone in normal lung and in animal models of pulmonary hypertension is unclear.1925 In this study population, captopril may have elicited little change in the pulmonary hemodynamics because angiotensin IL plays a minor role in the development and maintenance of primary pulmonary hypertension in humans.
The lungs of patients with pulmonary hypertension are less capable of extracting and metabolizing circulating catecholamines than are normal lungs.26 Thus, elevated catechols (evoked by the drop in systemic blood pressure after captopril), along with inadequate or deranged local catecholamine metabolism by the lung, may have negated beneficial pulmonary hemodynamic effects.
Captopril may act, in part, through other mechanisms of vasodilation, such as kininase II blockade (resultant increase in the circulating vasodilator bradykinin) .27-29 Why these alternative mechanisms of action fail to elicit even a mild change in pulmonary hemodynamics in primary pulmonary hypertensin is also unknown.
Although the effects of captopril in primary pulmonary hypertension were not particularly impressive, certain persons with this disease may derive some benefit. One of our seven patients is still taking captopril after the completion of the protocol because of continued mild subjective improvement. In general, however, efforts should probably be directed to evaluating other agents with greater potential for clinical and hemodynamic improvement.
